Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy
Key facts
- Who runs it
- University of Calgary
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 40 people, planned
- Started
- 27 May 2025
- Expected to end
- 30 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Psilocybin
- Record updated
- 9 September 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Other criteria
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Individuals of all sexes, gender identities, and ethnicities
- Ages 18 to 65 years at the time of screening
- Diagnosis of concussion based on the 2024 ACRM criteria
- Meet ICD-10 criteria for PSaC for at least 3-months to a maximum of 5 years
- Have an overall RPQ score ≥ 13 with 3 or more symptoms scored ≥3
- Limited lifetime use of serotonergic hallucinogens
- Ability to read/write English; An individual who meets any of the following criteria will be excluded from participation in this study:
- Severe or moderate substance use disorder other than nicotine in past 6 months
- Lifetime diagnosis of schizophrenia or bipolar disorders (or first or second-degree relative)
- Active suicidal ideation or serious attempt within the past 1 year
- Current pregnancy or nursing, trying to become pregnant
- Any notable abnormality on ECG or routine medical blood laboratory test
- Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia
- Epilepsy with a history of seizures
- Current or recent (within 12 weeks) participation in a clinical trial
- Cognitive impairment (SLUMS score <20)
- Suffered a moderate/severe TBI at least once in lifetime
- Any other circumstances that, in the opinion of the investigators, compromises participant safety
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this randomized controlled trial is to evaluate the safety, feasibility, and efficacy of psilocybin assisted therapy as an intervention to reduce symptom burden in adult patients (aged 18-65) with persisting symptoms after concussion (PSaC).
Read full original descriptionShow less
This trail will test the following 2 aims:
AIM 1 : To test the safety and feasibility of an active psilocybin-assisted psychotherapy to an active control for patients with PSaC.
AIM 2: To evaluate the efficacy of an active psilocybin-assisted psychotherapy compared to an active control as a treatment for PSaC.
Participants will be asked to:
* Complete a 2-part screening process * Attend a baseline assessment * Complete a psychoeducation preparation session(s) * Attend psilocybin administration session (receive high dose [25mg] or low dose psilocybin [1mg]) * Complete 5 weekly sessions of Acceptance and commitment therapy (ACT) * Repeat outcome measures at 1-week, 4 weeks, 3 months, and 6 months post-psilocybin administration (online only at 6 months).
The 2 groups in the trial
- High dose (25mg)Treatment being tested
High Dose (25mg) PEX010 (Oral Psilocybin), 25mg; single dose (20 participants) administered 24hrs prior to first ACT session
Treatment: Psilocybin
- Low dose (1mg)Existing treatment, for comparison
Low Dose (1mg) PEX010 (Oral Psilocybin), 1mg; single dose (20 participants)administered 24hrs prior to first ACT session
Treatment: Psilocybin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Double-blinded Controlled Trial for the Treatment of Persisting Symptoms After Concussion With Psilocybin-assisted Therapy: A Safety and Feasibility Trial
- Fit questions
- Built from NCT06615908, who can take part
- Record updated
- 9 September 2026